射频消融对比激光神经松解术治疗慢性鼻炎
回顾性队列研究比较单纯鼻后神经射频消融(RAPN)与联合CO₂激光鼻后神经松解(RPN3)治疗药物难治性慢性鼻炎的疗效。共分析101例患者(RPN3组76例,RAPN组25例),两组在1、3、6个月均显著改善症状,但RPN3组在1至6个月改善更优,尤其在流涕和鼻痒方面。
要点
- RAPN与RPN3均能有效改善药物难治性慢性鼻炎症状。
- RPN3在流涕和鼻痒症状改善上优于单纯RAPN。
- 两组rTNSS应答率分别达91%-100%(RPN3)和84%-96%(RAPN)。
核心结论
- RAPN与RPN3均对药物难治性慢性鼻炎有效,联合CO₂激光神经松解可提供更优症状缓解。
研究设计与样本
- 回顾性队列研究,单中心三级医疗中心,纳入2023年2月至2024年5月接受RAPN或RPN3的成人患者共101例(RPN3组76例,RAPN组25例)。
主要发现
- 两组基线rTNSS和NOSE评分无显著差异(P=.144和.414)。
- 两组在1、3、6个月随访时rTNSS和NOSE评分均显著改善(P<.001)。
- RPN3组在1至6个月改善程度显著优于RAPN组(P=.039-.045),尤其在流涕和鼻痒子评分上(P=.003-.039)。
- rTNSS应答率RPN3组为91%-100%,RAPN组为84%-96%。
关键数值与推荐
- 纳入标准:24小时回顾性鼻部症状总分(rTNSS)≥3,流涕评分≥1,NOSE评分≥11。
- 排除标准:慢性鼻窦炎、鼻息肉、凝血功能障碍。
- 主要终点:治疗后1、3、6个月rTNSS、NOSE评分变化及应答率(较基线改善≥30%)。
临床怎么用
- 对于药物难治性慢性鼻炎患者,可考虑RAPN或RPN3,联合CO₂激光神经松解可能更有利于改善流涕和鼻痒。
局限性
- 回顾性研究设计,样本量较小且分组不均衡(RPN3组76例 vs RAPN组25例),单中心结果可能需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the clinical outcomes of radiofrequency ablation of the intraturbinate segment of the posterior nasal nerve (RAPN) alone versus combined RAPN with CO₂ laser posterior nasal nerve neurolysis (RPN3) in patients with chronic rhinitis refractory to medical therapy. STUDY DESIGN: Retrospective cohort study. SETTING: Single tertiary care center. METHODS: Adult patients with chronic rhinitis unresponsive to medical treatment for over 6 months who underwent either RAPN or RPN3 between February 2023 and May 2024 were included. Inclusion criteria were 24-hour reflective total nasal symptom score (rTNSS) ≥ 3, rhinorrhea score ≥1, and NOSE score ≥11. Exclusion criteria included chronic rhinosinusitis, nasal polyps, and coagulopathy. Demographics and comorbidities were documented. Primary endpoints were changes in rTNSS, NOSE scores, and response rate (≥30% improvement from baseline) at 1-, 3-, and 6-months posttreatment. RESULTS: A total of 101 patients were analyzed (RPN3: 76; RAPN: 25). Baseline rTNSS and NOSE scores were comparable between the two groups (P = .144 and .414, respectively). Both groups demonstrated significant improvements in rTNSS and NOSE scores at all follow-up points (P < .001). From 1 to 6 months, RPN3 achieved significantly greater improvements compared to RAPN (P = .039-.045), particularly in the rhinorrhea and nasal itching sub-scores (P = .003-.039). Response rates for rTNSS ranged from 91% to 100% in the RPN3 group and 84% to 96% in the RAPN group. CONCLUSION: Both RAPN and RPN3 are effective in treating chronic rhinitis unresponsive to medication. The addition of CO₂ laser posterior nasal nerve neurolysis (RPN3) provides superior symptomatic relief, particularly for rhinorrhea and nasal itching.
引用
- Lin CC, Hwang YL, Liao JY, et al. Radiofrequency Ablation Versus Laser Neurolysis of the Posterior Nasal Nerve in Patients With Chronic Rhinitis. Otolaryngol Head Neck Surg. 2026. PMID: 41649252. doi:10.1002/ohn.70156
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。